Biogen's pricey, controversial new Alzheimer's drug was a shock to the bureaucracy that governs who can get drugs, and who pays for them.
Alzheimer's Patients in Limbo
Comment
Show comments
Hide Comments
Biogen's pricey, controversial new Alzheimer's drug was a shock to the bureaucracy that governs who can get drugs, and who pays for them.
